San Francisco-based startup Teal Health, which provides at-home cervical cancer tests, has secured $10m in seed funding, bringing its total to $23m. Teal, which aims to improve screening rates and ongoing engagement with care, has developed an at-home kit and telehealth platform, with patients extracting their own samples using the company’s device. The investment round was led by Emerson Collective and Forerunner and also included participation from Labcorp, Serena Ventures and Metrodora.
8 Way AI Can Optimize Revenue Cycle Management in 2025
Revenue Cycle Management, essential for healthcare operations, is facing significant challenges. AI might prove to be a game-changer for RCM, as it can automate repetitive
